177 related articles for article (PubMed ID: 26010746)
1. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.
Hargadon KM; Bishop JD; Brandt JP; Hand ZC; Ararso YT; Forrest OA
Immunol Cell Biol; 2016 Jan; 94(1):24-38. PubMed ID: 26010746
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
3. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
5. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.
Camporeale A; Boni A; Iezzi G; Degl'Innocenti E; Grioni M; Mondino A; Bellone M
Cancer Res; 2003 Jul; 63(13):3688-94. PubMed ID: 12839960
[TBL] [Abstract][Full Text] [Related]
6. Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity.
Zhang X; Moyana T; Quereshi M; Xiang J
Cancer Biother Radiopharm; 2006 Feb; 21(1):74-80. PubMed ID: 16480334
[TBL] [Abstract][Full Text] [Related]
7. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
9. INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells.
Kasamatsu J; Azuma M; Oshiumi H; Morioka Y; Okabe M; Ebihara T; Matsumoto M; Seya T
J Immunol; 2014 Nov; 193(10):5199-207. PubMed ID: 25320282
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors.
Hargadon KM; Forrest OA; Reddy PR
Cell Immunol; 2012; 272(2):275-82. PubMed ID: 22051048
[TBL] [Abstract][Full Text] [Related]
11. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
12. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
[TBL] [Abstract][Full Text] [Related]
13. Fusion induced reversal of dendritic cell maturation: an altered expression of inflammatory chemokine and chemokine receptors in dendritomas.
Branham-O'Connor M; Li J; Kotturi HS; Yu X; Wagner TE; Wei Y
Oncol Rep; 2010 Feb; 23(2):545-50. PubMed ID: 20043120
[TBL] [Abstract][Full Text] [Related]
14. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
15. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
16. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
17. miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1.
Lind EF; Millar DG; Dissanayake D; Savage JC; Grimshaw NK; Kerr WG; Ohashi PS
J Immunol; 2015 Nov; 195(10):4632-40. PubMed ID: 26447227
[TBL] [Abstract][Full Text] [Related]
18. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
20. Innate and adoptive immune cells contribute to natural resistance to systemic metastasis of B16 melanoma.
Umeshappa CS; Zhu Y; Bhanumathy KK; Omabe M; Chibbar R; Xiang J
Cancer Biother Radiopharm; 2015 Mar; 30(2):72-8. PubMed ID: 25714591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
